0001514946 false 0001514946 2021-08-02 2021-08-02

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

_______________________

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): August 3, 2021

PICTURE  

AXIM BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-54296

 

27-4092986

(State or other jurisdiction of incorporation)

 

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

6191 Cornerstone Court, E., Suite 114

San Diego, California

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

858-923-4422

(Registrant’s telephone number, including area code)

 

(Former name if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 1.01 Entry into a Material Definitive Agreement.

 

On August 3, 2021, AXIM Biotechnologies, Inc. issued a press release which announced that the company had entered into a Binding Term Sheet Agreement with Advanced Tear Diagnostics, LLC (“ATD”) wherein the AXIM agreed to acquire certain Eye Care technology and assets from ATD in exchange for 7,000,000 restricted shares of the Company’s common stock. The assets include two FDA authorizations and approvals for the commercial sale of two ophthalmic diagnostic lab tests. AXIM and ATD intend to enter into Definitive Documents for the transaction to close no later than October 1, 2021.  The Binding Term Sheet will remain in full force and effect until such time as the Definitive Documents are executed by the parties.

 

Item 7.01 Regulation FD Disclosure

 

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 - Financial Statements and Exhibits

 

(d) Exhibits

 

99.1

Press Release


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AXIM BIOTECHNOLOGIES, INC.

 

 

 

Dated: August 3, 2021

By:

/s/ John Huemoeller, II

 

 

 

Name: John Huemoeller, II

 

 

Chief Executive Officer

 

Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Axim Biotechnologies (QB) Charts.
Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Axim Biotechnologies (QB) Charts.